help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Melmed, S.
Right arrow Articles by Frohman, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Melmed, S.
Right arrow Articles by Frohman, L. A.

Journal of Clinical Endocrinology & Metabolism, Vol 67, 395-399, Copyright © 1988 by Endocrine Society


ARTICLES

Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor

S Melmed, FH Ziel, GD Braunstein, T Downs and LA Frohman
Department of Medicine, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles 90048.

A 59-yr-old woman with a disseminated carcinoid tumor was evaluated for acromegaly. She had previously undergone a hypophysectomy for acromegaly and an enlarged pituitary, with a reduction in her serum GH levels from 100 to 4 micrograms/L. Recurrence of acromegalic symptoms 2 yr later was accompanied by elevated serum GH (16 micrograms/L) and insulin-like growth factor I (IGF-I; 528 micrograms/L) and plasma GHRH levels (12 micrograms/L; normal, less than 30 ng/L). Computed tomographic scan did not reveal pituitary enlargement. Metastatic carcinoid tissue in bone removed at biopsy contained GHRH (100 pg/mg tissue). High performance liquid chromatography of plasma GHRH revealed predominantly GHRH-(3-40)-OH, a biologically inactive GHRH metabolite, along with mature GHRH forms, while carcinoid tissue contained both GHRH-(1-40)-OH and GHRH-(1-44)-NH2. Treatment with pergolide initially resulted in reduction in serum GH and IGF-I levels and amelioration of symptoms of acromegaly. However, after 14 months of pergolide therapy, serum GH levels increased despite administration of up to 1000 micrograms pergolide/day. Plasma GHRH levels remained elevated throughout the treatment period. Subsequent treatment with SMS 201-995, a long-acting somatostatin analog, for over 1 yr resulted in sustained reductions of ectopic GHRH secretion, GH hypersecretion, and IGF-I levels. Plasma GHRH levels correlated with simultaneously measured serum GH levels in response to acute SMS 201-995 administration. SMS 201-995 was an effective medical treatment for acromegaly caused by ectopic GHRH production in this patient.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. C. Zatelli, P. Maffei, D. Piccin, C. Martini, F. Rea, D. Rubello, A. Margutti, M. D. Culler, N. Sicolo, and E. C. d. Uberti
Somatostatin Analogs in Vitro Effects in a Growth Hormone-Releasing Hormone-Secreting Bronchial Carcinoid
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2104 - 2109.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
R. Hage, A. B. de la Riviere, C.A. Seldenrijk, and J.M. M. van den Bosch
Update in Pulmonary Carcinoid Tumors: A Review Article
Ann. Surg. Oncol., July 1, 2003; 10(6): 697 - 704.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
A. Bhansali, S S. Rana, S. Bhattacharya, R. Muralidharan, R. J Dash, and A. K Banerjee
Acromegaly: a Rare Manifestation of Bronchial Carcinoid
Asian Cardiovasc Thorac Ann, September 1, 2002; 10(3): 273 - 274.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Van den Bruel, J. Fevery, J. Van Dorpe, L. Hofland, and R. Bouillon
Hormonal and Volumetric Long Term Control of a Growth Hormone-Releasing Hormone-Producing Carcinoid Tumor
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3162 - 3169.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. R. Drange and S. Melmed
Long-Acting Lanreotide Induces Clinical and Biochemical Remission of Acromegaly Caused by Disseminated Growth Hormone-Releasing Hormone-Secreting Carcinoid
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3104 - 3109.
[Abstract] [Full Text]


Home page
CLIN PEDIATRHome page
J. F. Sotos
Overgrowth
Clinical Pediatrics, November 1, 1996; 35(11): 577 - 590.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society